Ammarin Suwan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Ammarin Suwan has a total of 23 co-authors. Here are the top co-authors by number of shared publications:
Krasean Panyakhamlerd
Division of Gender, Sexual, and Climacteric Medicine, Department of Obstetrics and Gynecology, Faculty of Medicine, Chulalongkorn University
6 shared publicationsJarika Vatrasresth
Reproductive Medicine Division, Departments of Obstetrics and Gynecology, Faculty of Medicine, King Chulalongkorn Memorial Hospital, Chulalongkorn University, Bangkok, Thailand
2 shared publications- Panachai Nimitpanya
Department of Obstetrics and Gynecology, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand
2 shared publications Suchanant Chavaengkiat
Division of Gender, Sexual, and Climacteric Medicine, Department of Obstetrics and Gynecology, Faculty of Medicine, Chulalongkorn University
2 shared publicationsThanapob Bumphenkiatikul
Center of Excellence in Transgender Health (CETH), Chulalongkorn University, Bangkok, Thailand
2 shared publications- Areepan Sophonsritsuk
Reproductive Endocrinology and Infertility Unit, Department of Obstetrics and Gynaecology, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand
1 shared publication
Latest Publications
- Open Access
- 23 February 2026
- Published by Elsevier in Obesity Pillars
- Vol. 18, 100255
Obesity and female reproductive health in Asian population
- 23 February 2026
- Published by Elsevier in Obesity Pillars
- Vol. 18, 100255
Open AccessObesity and female reproductive health in Asian population
- 4 March 2025
- Published by Taylor & Francis in International Journal of Transgender Health
- Vol. 27 (2) , 930-938
Short-term effects of testosterone on quality of life and sexual function among hormone naïve Thai transmasculine individuals
Testosterone therapy is a standard intervention for improving both physical and mental health in transmasculine individuals. The aim of this study is to identify the effects of testosterone on the quality of life and sexual function among hormone-naïve transmasculine individuals in Thailand. This prospective study was conducted at King Chulalongkorn Memorial Hospital, Bangkok, Thailand from September 2022 to February 2024. Transmasculine individuals who met the inclusion criteria were invited to complete two questionnaires: the World Health Organization Quality of Life BREF THAI (WHO-QOL-BREF-THAI) and the female sexual function index (FSFI). Testosterone enanthate, 250 milligrams, was administered intramuscularly every 4 wk. Both questionnaires were reevaluated at 12 wk after initiation of testosterone therapy. A total of 55 hormone naïve transmasculine individuals were recruited. After a 12-wk period of testosterone therapy, the WHO-QOL-BREF-THAI mean total score was significantly higher compared to baseline (94.3 versus 101.4 out of 130, p < 0.001). Moreover, the mean scores in all particular WHO-QOL-BREF-THAI domains were also significantly different. Percentages of participants who reported good quality of life according to WHO-QOL-BREF-THAI score at 12 wk were significantly higher compared to baseline (69.1% versus 43.6%, p = 0.004). Among 34 participants who were sexually active throughout the study, there were significantly better total FSFI, desire domain, and orgasm domain scores at 12 wk of treatment compared to baseline (28.0 vs 24.2, 4.5 vs 3.4, and 4.6 vs 3.7, p = 0.022, <0.001 and 0.017, respectively). Hormone naïve-transmasculine individuals demonstrated significantly higher overall quality of life as early as 12 wk after testosterone therapy. Among transmasculine individuals who were sexually active, total FSFI, sexual desire, and orgasm scores were also significantly better compared to baseline. The longer-term effects of testosterone therapy on quality of life and sexual function among TM need to be elucidated in further studies.
- 4 March 2025
- Published by Taylor & Francis in International Journal of Transgender Health
- Vol. 27 (2) , 930-938
Short-term effects of testosterone on quality of life and sexual function among hormone naïve Thai transmasculine individuals
Testosterone therapy is a standard intervention for improving both physical and mental health in transmasculine individuals. The aim of this study is to identify the effects of testosterone on the quality of life and sexual function among hormone-naïve transmasculine individuals in Thailand. This prospective study was conducted at King Chulalongkorn Memorial Hospital, Bangkok, Thailand from September 2022 to February 2024. Transmasculine individuals who met the inclusion criteria were invited to complete two questionnaires: the World Health Organization Quality of Life BREF THAI (WHO-QOL-BREF-THAI) and the female sexual function index (FSFI). Testosterone enanthate, 250 milligrams, was administered intramuscularly every 4 wk. Both questionnaires were reevaluated at 12 wk after initiation of testosterone therapy. A total of 55 hormone naïve transmasculine individuals were recruited. After a 12-wk period of testosterone therapy, the WHO-QOL-BREF-THAI mean total score was significantly higher compared to baseline (94.3 versus 101.4 out of 130, p < 0.001). Moreover, the mean scores in all particular WHO-QOL-BREF-THAI domains were also significantly different. Percentages of participants who reported good quality of life according to WHO-QOL-BREF-THAI score at 12 wk were significantly higher compared to baseline (69.1% versus 43.6%, p = 0.004). Among 34 participants who were sexually active throughout the study, there were significantly better total FSFI, desire domain, and orgasm domain scores at 12 wk of treatment compared to baseline (28.0 vs 24.2, 4.5 vs 3.4, and 4.6 vs 3.7, p = 0.022, <0.001 and 0.017, respectively). Hormone naïve-transmasculine individuals demonstrated significantly higher overall quality of life as early as 12 wk after testosterone therapy. Among transmasculine individuals who were sexually active, total FSFI, sexual desire, and orgasm scores were also significantly better compared to baseline. The longer-term effects of testosterone therapy on quality of life and sexual function among TM need to be elucidated in further studies.
- 1 December 2024
- Published by SAGE Publications in Transgender Health
- Vol. 9 (6) , 501-507
The Effects of Testosterone on Bone Turnover Markers Among Hormone-Naive Transgender Men
Purpose: Transgender medicine has become rapidly recognized and evolving in the health care system. The consequences of hormone therapy are among the most concerning health issues in the transgender population. This study aims to compare bone turnover markers before and after testosterone administration in hormone-naive transgender men. Methods: This prospective study included 20 hormone-naive transgender men. Comparisons of serum C-terminal cross-linking telopeptide of type I collagen (CTX) at baseline with 12 weeks and 24 weeks were analyzed using Wilcoxon signed-rank test. Serum procollagen type I N-propeptide (P1NP) and osteocalcin levels at 24 weeks compared to baseline were also assessed. Pearson's correlation coefficient analysis was used to compare the correlation between serum bone turnover markers and sex hormone levels. Results: At 12 weeks after testosterone administration, significant higher serum CTX level compared to baseline ( p -value 0.035) was demonstrated. At 24 weeks after testosterone administration, there were significant differences in serum CTX, P1NP, and osteocalcin levels compared to baseline ( p -value 0.019, <0.001, and 0.003, respectively). Serum CTX, P1NP, and osteocalcin levels significantly increased 28.30%, 44.26%, and 21.89%, respectively, at 24 weeks after testosterone treatment. There was a moderate negative correlation between serum CTX and estradiol level. Conclusion: Testosterone administration in transgender men significantly increased the levels of bone turnover markers. Further, well-controlled studies of bone health in transgender men are required to prove and assess the other aspects of bone status over a long-term follow-up period. Thai Clinical Trial Registry identification number TCTR20220817002.
- 1 December 2024
- Published by SAGE Publications in Transgender Health
- Vol. 9 (6) , 501-507
The Effects of Testosterone on Bone Turnover Markers Among Hormone-Naive Transgender Men
Purpose: Transgender medicine has become rapidly recognized and evolving in the health care system. The consequences of hormone therapy are among the most concerning health issues in the transgender population. This study aims to compare bone turnover markers before and after testosterone administration in hormone-naive transgender men. Methods: This prospective study included 20 hormone-naive transgender men. Comparisons of serum C-terminal cross-linking telopeptide of type I collagen (CTX) at baseline with 12 weeks and 24 weeks were analyzed using Wilcoxon signed-rank test. Serum procollagen type I N-propeptide (P1NP) and osteocalcin levels at 24 weeks compared to baseline were also assessed. Pearson's correlation coefficient analysis was used to compare the correlation between serum bone turnover markers and sex hormone levels. Results: At 12 weeks after testosterone administration, significant higher serum CTX level compared to baseline ( p -value 0.035) was demonstrated. At 24 weeks after testosterone administration, there were significant differences in serum CTX, P1NP, and osteocalcin levels compared to baseline ( p -value 0.019, <0.001, and 0.003, respectively). Serum CTX, P1NP, and osteocalcin levels significantly increased 28.30%, 44.26%, and 21.89%, respectively, at 24 weeks after testosterone treatment. There was a moderate negative correlation between serum CTX and estradiol level. Conclusion: Testosterone administration in transgender men significantly increased the levels of bone turnover markers. Further, well-controlled studies of bone health in transgender men are required to prove and assess the other aspects of bone status over a long-term follow-up period. Thai Clinical Trial Registry identification number TCTR20220817002.
- 1 December 2023
- Published by SAGE Publications in Transgender Health
- Vol. 8 (6) , 509-515
Mental Health of Transmasculine Adults Receiving Gender-Affirming Hormone Therapy in Thailand
Purpose: Many studies have shown conflicting results regarding mental health among transmasculine adults or transgender men (TM). This study aimed to identify the prevalence of depression among Thai TM receiving gender-affirming hormone therapy (GAHT). Methods: All TM, over 18 years of age, who received GAHT for at least three consecutive months were invited to complete a self-report questionnaire that covered participants' demographic and clinical data. Mental health, including depression, anxiety, and quality of life (QoL), was assessed. We reported the prevalence of mental illnesses and examined the correlations between mental health scores and other associated data. Results: A total of 84 TM were included in the analysis. Major depression and generalized anxiety disorder were detected in 14.3% and 3.6%, respectively. Depression severity was negatively associated with age and QoL. Depression and anxiety severity were found to be positively associated. Conclusions: Compared with the general Thai population, the prevalence of mental health problems among Thai TM receiving GAHT was higher. Age of maturity may be a potential mental health protective factor, and assessment in younger individuals may benefit mental health.
- 1 December 2023
- Published by SAGE Publications in Transgender Health
- Vol. 8 (6) , 509-515
Mental Health of Transmasculine Adults Receiving Gender-Affirming Hormone Therapy in Thailand
Purpose: Many studies have shown conflicting results regarding mental health among transmasculine adults or transgender men (TM). This study aimed to identify the prevalence of depression among Thai TM receiving gender-affirming hormone therapy (GAHT). Methods: All TM, over 18 years of age, who received GAHT for at least three consecutive months were invited to complete a self-report questionnaire that covered participants' demographic and clinical data. Mental health, including depression, anxiety, and quality of life (QoL), was assessed. We reported the prevalence of mental illnesses and examined the correlations between mental health scores and other associated data. Results: A total of 84 TM were included in the analysis. Major depression and generalized anxiety disorder were detected in 14.3% and 3.6%, respectively. Depression severity was negatively associated with age and QoL. Depression and anxiety severity were found to be positively associated. Conclusions: Compared with the general Thai population, the prevalence of mental health problems among Thai TM receiving GAHT was higher. Age of maturity may be a potential mental health protective factor, and assessment in younger individuals may benefit mental health.
- Open Access
- 13 October 2021
- Published by Springer Nature in BMC Women's Health
- Vol. 21 (1) , 1-10
Effects of early estradiol valerate administration on bone turnover markers in surgically induced menopausal women
Background: Compared with a natural process, surgically induced menopausal women have a higher bone loss rate. This study aims to evaluate early treatment with estradiol valerate on bone turnover markers after surgically induced menopause. Methods: This prospective study included 41 pre and perimenopausal women who underwent hysterectomy with oophorectomy for benign gynecologic conditions. Two weeks after the operation, all participants were assessed for menopausal hormone therapy (MHT) indications. Estrogen therapy was prescribed for those who had indications and accepted treatment (hormone treatment group). The others who had no MHT indication were allocated to the no-treatment group. Serum CTX and P1NP levels at preoperative and 12 weeks postoperative were measured and set as the primary outcome. Within the same group, serum CTX and P1NP before and after surgical menopause were analyzed using Wilcoxon signed-rank test. ANCOVA was used to compare serum CTX and P1NP at 12 weeks after surgical menopause between the two groups. Spearman's rank correlation coefficient analysis analyzed the correlation between age and baseline bone turnover markers. A p-value of < 0.05 was considered statistically significant. Results: At 12 weeks after surgery, there were no significant differences in serum CTX and P1NP levels in the hormone treatment group compared to baseline. In contrast, serum CTX and P1NP levels were significantly elevated among women who did not receive hormone treatment (p-value < 0.001 and 0.002, respectively). Serum CTX and P1NP at 12 weeks were significantly different between the two groups (p-value < 0.001 and 0.004, respectively). Conclusion: Early estrogen administration with oral estradiol valerate could significantly suppress the high bone remodeling in surgically induced menopausal women. Trial registration Thai Clinical Trial Registry identification number TCTR20190808004, retrospective registered since 2019-08-08. http://www.thaiclinicaltrials.org/show/TCTR20190808004.
- 13 October 2021
- Published by Springer Nature in BMC Women's Health
- Vol. 21 (1) , 1-10
Open AccessEffects of early estradiol valerate administration on bone turnover markers in surgically induced menopausal women
Background: Compared with a natural process, surgically induced menopausal women have a higher bone loss rate. This study aims to evaluate early treatment with estradiol valerate on bone turnover markers after surgically induced menopause. Methods: This prospective study included 41 pre and perimenopausal women who underwent hysterectomy with oophorectomy for benign gynecologic conditions. Two weeks after the operation, all participants were assessed for menopausal hormone therapy (MHT) indications. Estrogen therapy was prescribed for those who had indications and accepted treatment (hormone treatment group). The others who had no MHT indication were allocated to the no-treatment group. Serum CTX and P1NP levels at preoperative and 12 weeks postoperative were measured and set as the primary outcome. Within the same group, serum CTX and P1NP before and after surgical menopause were analyzed using Wilcoxon signed-rank test. ANCOVA was used to compare serum CTX and P1NP at 12 weeks after surgical menopause between the two groups. Spearman's rank correlation coefficient analysis analyzed the correlation between age and baseline bone turnover markers. A p-value of < 0.05 was considered statistically significant. Results: At 12 weeks after surgery, there were no significant differences in serum CTX and P1NP levels in the hormone treatment group compared to baseline. In contrast, serum CTX and P1NP levels were significantly elevated among women who did not receive hormone treatment (p-value < 0.001 and 0.002, respectively). Serum CTX and P1NP at 12 weeks were significantly different between the two groups (p-value < 0.001 and 0.004, respectively). Conclusion: Early estrogen administration with oral estradiol valerate could significantly suppress the high bone remodeling in surgically induced menopausal women. Trial registration Thai Clinical Trial Registry identification number TCTR20190808004, retrospective registered since 2019-08-08. http://www.thaiclinicaltrials.org/show/TCTR20190808004.
- 17 July 2021
- Published by Springer Nature in European Journal of Plastic Surgery
- Vol. 45 (1) , 101-107
The sexual function among transgender women who have undergone gender-affirming surgery using penile skin inversion vaginoplasty in Thailand
- 17 July 2021
- Published by Springer Nature in European Journal of Plastic Surgery
- Vol. 45 (1) , 101-107
The sexual function among transgender women who have undergone gender-affirming surgery using penile skin inversion vaginoplasty in Thailand
- Open Access
- 1 July 2021
- Published by Springer Nature in Research Square
Effects of Early Estradiol Valerate Administration On Bone Turnover Markers in Surgically Induced Menopausal Women
Background Compared with natural process, surgically induced menopausal women have a higher bone loss rate. The objectives of this study were to evaluate effects of early treatment with estradiol valerate on the bone turnover markers levels after surgically induced menopause. Methods This prospective study enrolled 48 pre and perimenopausal women who underwent hysterectomy with oophorectomy for benign gynecologic conditions. Two weeks after surgery, all participants were assessed for menopausal hormone therapy (MHT) indications. Estrogen therapy was prescribed for those who had indication and accepted treatment (hormone treatment group). The others who had no MHT indication were allocated to no treatment group. Serum CTX and P1NP levels were measured at preoperative and 12 weeks postoperative. Results The median serum CTX and P1NP at 12 weeks were significantly different between two groups (p-value < 0.001 and 0.004, respectively). Median serum CTX and P1NP levels of women in the hormone treatment group were 55% and 40% lower than the women in no treatment group, respectively. At 12 weeks after surgery, serum CTX and P1NP levels were significantly elevated among women who did not receive hormone treatment (p-value < 0.001 and 0.002). In contrast, there were no significant change in the hormone treatment group. Conclusion Surgically induced menopausal women who received early estradiol valerate therapy had significantly lower levels of serum CTX and serum P1NP compared to women who did not receive treatment at 12 weeks after surgeries. This indicated that early estradiol valerate treatment could significantly suppress high bone-remodeling process in women with acute estrogen deprivation conditions. Trial registration: Thai Clinical Trial Registry identification number TCTR20190808004, retrospective registered since 2019-08-08. http://www.thaiclinicaltrials.org/show/TCTR20190808004
- 1 July 2021
- Published by Springer Nature in Research Square
Open AccessEffects of Early Estradiol Valerate Administration On Bone Turnover Markers in Surgically Induced Menopausal Women
Background Compared with natural process, surgically induced menopausal women have a higher bone loss rate. The objectives of this study were to evaluate effects of early treatment with estradiol valerate on the bone turnover markers levels after surgically induced menopause. Methods This prospective study enrolled 48 pre and perimenopausal women who underwent hysterectomy with oophorectomy for benign gynecologic conditions. Two weeks after surgery, all participants were assessed for menopausal hormone therapy (MHT) indications. Estrogen therapy was prescribed for those who had indication and accepted treatment (hormone treatment group). The others who had no MHT indication were allocated to no treatment group. Serum CTX and P1NP levels were measured at preoperative and 12 weeks postoperative. Results The median serum CTX and P1NP at 12 weeks were significantly different between two groups (p-value < 0.001 and 0.004, respectively). Median serum CTX and P1NP levels of women in the hormone treatment group were 55% and 40% lower than the women in no treatment group, respectively. At 12 weeks after surgery, serum CTX and P1NP levels were significantly elevated among women who did not receive hormone treatment (p-value < 0.001 and 0.002). In contrast, there were no significant change in the hormone treatment group. Conclusion Surgically induced menopausal women who received early estradiol valerate therapy had significantly lower levels of serum CTX and serum P1NP compared to women who did not receive treatment at 12 weeks after surgeries. This indicated that early estradiol valerate treatment could significantly suppress high bone-remodeling process in women with acute estrogen deprivation conditions. Trial registration: Thai Clinical Trial Registry identification number TCTR20190808004, retrospective registered since 2019-08-08. http://www.thaiclinicaltrials.org/show/TCTR20190808004